INFORMED CONSENT FOR MEDICATION
Dosage and / or Side Effect information last revised on 11/09/2015

Completion of this form is voluntary. If not completed, the medication cannot be administered without a court order unless in an emergency. This consent is maintained in the client’s record and is accessible to authorized users.

<table>
<thead>
<tr>
<th>MEDICATION CATEGORY</th>
<th>MEDICATION</th>
<th>RECOMMENDED DAILY TOTAL DOSAGE RANGE</th>
<th>ANTICIPATED DOSAGE RANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticonvulsant/Pain reliever</td>
<td>Lyrica (pregabalin)</td>
<td>50-600 mg for adults (no safety or efficacy data for children)</td>
<td></td>
</tr>
</tbody>
</table>

The anticipated dosage range is to be individualized, may be above or below the recommended range but no medication will be administered without your informed and written consent.

Recommended daily total dosage range of manufacturer, as stated in *Physician’s Desk Reference* (PDR) or another standard reference.

This medication will be administered □ Orally □ Injection □ Other – Specify:

1. **Reason for Use of Psychotropic Medication and Benefits Expected**
   (note if this is ‘Off Label’ Use)
   Include DSM 5 diagnosis or the diagnostic “working hypothesis.”

2. **Alternative mode(s) of treatment other than or in addition to medications include**
   Note: Some of these would be applicable only in an inpatient environment.
   □ Environment and/or staff changes □ Rehabilitation treatments/therapy (OT, PT, AT)
   □ Positive redirection and staff interaction □ Treatment programs and approaches (habilitation)
   □ Individual and/or group therapy □ Use of behavior intervention techniques
   **Other Alternatives:**

3. **Probable consequences of NOT receiving the proposed medication are**
   **Impairment of** □ Work Activities □ Family Relationships □ Social Functioning
   **Possible increase in symptoms leading to potential**
   □ Use of seclusion or restraint □ Limits on recreation and leisure activities
   □ Limits on access to possessions □ Intervention of law enforcement authorities
   □ Limits on personal freedoms □ Risk of harm to self or others
   □ Limit participation in treatment and activities
   **Other consequences**

   **Note:** These consequences may vary, depending upon whether or not the individual is in an inpatient setting. It is also possible that in unusual situations, little or no adverse consequences may occur if the medications are not administered.

See Page 2

Client Initial ___________ Date ______________
4. Possible side effects, warnings and cautions associated with this medication are listed below. This is not an all-inclusive list but is representative of items of potential clinical significance to you. For more information on this medication, you may consult further with your physician or refer to a standard text such as the PDR. As part of monitoring some of these potential side effects, your physician may order laboratory or other tests. The treatment team will closely monitor individuals who are unable to readily communicate side effects, in order to enhance care and treatment.

Continued – Possible side effects, warnings and cautions associated with this medication.

**Most Common Side Effects** include swelling of the hands, feet, or lower legs; dry mouth, constipation, weight gain, headache, dizziness, sedation, fatigue, somnolence, incoordination, blurred vision, double vision, disturbance in thinking, and runny nose.

Check with your prescriber as soon as possible if you experience: clumsiness or unsteadiness/impaired balance, peripheral edema (swelling), or changes in mood or thoughts.

**Less common Side Effects** include increased appetite, vomiting, decreased platelet production, muscle aches or weakness, muscle spasms, accidental injury, lack of energy, confusion, disturbance of speech, insomnia, euphoria, tremor, vertigo, and infection.

**Rare Side Effects** include jaundice, elevated liver enzymes, hypersensitivity reaction (rash, blisters, hives, shortness of breath), increased creatine kinase levels (musculoskeletal), suicidal thoughts, amnesia, angioedema.

**Caution:** This medication has the potential to impair judgment, thinking, and motor skills. Be cautious about operating machinery, including automobiles until reasonably certain that this medication does not affect you. Significant dizziness and somnolence or sedation have been reported.

Avoid stopping this medication abruptly as there have been reports of withdrawal seizure and other adverse effects (eg, insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea) may be precipitated by abrupt discontinuation; taper off the medication gradually.

**Warning** Suicidal ideation and behavior, worsening of depression and unusual changes in mood or behavior may occur as early as 1 week following the initiation of this medication. Patients taking this medication should be monitored for the emergence of worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Concerns should be reported immediately to your healthcare provider.

Patients, their caregivers, and families should be informed of that Antiepileptic Drugs (AEDs) increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or thoughts of self-harm. Concerns should be reported immediately to healthcare providers.

**Syndrome Note**

See PDR or US Hospital Formulary Service for all-inclusive list of side effects.

By my signature below, I GIVE consent for the named medication on Page 1 and anticipated dosage range. My signature also indicates that I understand the following:

1. I can refuse to give consent or can withdraw my consent at any time with written notification to the institution director or designee. This will not affect my right to change my decision at a later date. If I withdraw consent after a medication is started, I realize that the medication may not be discontinued immediately. Rather it will be tapered as rapidly as medically safe and then discontinued so as to prevent an adverse medical consequence, such as seizures, due to rapid medication withdrawal.

2. Questions regarding this medication can be discussed with the Interdisciplinary Team, including the physician. The staff contact person can assist in making any necessary arrangements.

3. Questions regarding any behavior support plan or behavior intervention plan, which correspond with the use of the medication, can be directed to the client’s social worker, case manager or psychologist.

4. I have the right to request a review at any time of my record, pursuant to § 51.30(4)(d) or § 51.30(5)(b).

5. I have a legal right to file a complaint if I feel that client rights have been inappropriately restricted. The client’s social worker, case manager or agency / facility client rights specialist may be contacted for assistance.

6. My consent permits the dose to be changed within the anticipated dosage range without signing another consent.

7. I understand the reasons for the use of the medication, its potential risks and benefits, other alternative treatment(s) and the probable consequences, which may occur if the proposed medication is not given. I have been given adequate time to study the information and find the information to be specific, accurate and complete.

8. This medication consent is for a period effective immediately and not to exceed fifteen (15) months from the date of my signature. The need for and continued use of this medication will be reviewed at least quarterly by the Interdisciplinary Team. The goal, on behalf of the client, will be to arrive at and maintain the client at the minimum effective dose.
### SIGNATURES

<table>
<thead>
<tr>
<th>Client – If Presumed Competent to Consent/Parent of Minor/Guardian (POA-HC)</th>
<th>Relationship to Client</th>
<th>DATE Signed</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Self</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Parent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guardian (POA-HC)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Staff Present at Oral Discussion</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Client / Parent of Minor / Guardian (POA-HC) Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

As parent/guardian (POA-HC) was not available for signature, he/she was verbally informed of the information in this consent.

### Verbal Consent

<table>
<thead>
<tr>
<th>Obtained by – PRINT – Staff Name</th>
<th>Date Obtained</th>
<th>Written Consent Received</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Obtained from – PRINT – Parent / Guardian (POA-HC) Name</th>
<th>Date Expires</th>
<th>Date Received</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>